MD BIOLAB CO LTD has a total of 12 patent applications. Its first patent ever was published in 2018. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals are UNIV MEDYCZNY W BIAŁYMSTOKU, JIANGSU PROVINCIAL ACADEMY TRADITIONAL CHINESE MEDICINE and ZD EHKOLOGICHESKOJ TEKHN I EHKOPITANIJA DIOD AOOT.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | EPO (European Patent Office) | 1 | |
#4 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Kim Soo Youl | 12 |
#2 | Park Jong Bae | 2 |
#3 | Woo Sang Myung | 2 |
#4 | Jang Hyon Chol | 2 |
#5 | Rha Sun Young | 2 |
#6 | Han Sung Sik | 2 |
#7 | Park Sang Jae | 2 |
#8 | Kang Seok Gu | 2 |
#9 | Beom Seung Hoon | 2 |
#10 | Sim Sung Hoon | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020159203A1 | Composition comprising streptonigrin and anticancer agent for preventing or treating brain tumor | |
WO2020159171A2 | Composition comprising streptonigrin and anticancer agent for preventing or treating colorectal cancer | |
KR20200059178A | Pharmaceutical composition for preventing or treating cancer comprising streptonigrin and anticancer agent |